Original
Coste-efectividad y seguridad de telaprevir y boceprevir para el tratamiento de la hepatitis C crónica en la práctica clínica
Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice
Leído
4343
Vecesse ha leído el artículo
824
Total PDF
3519
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 10 | 5 | 15 |
| 2025 11 | 34 | 12 | 46 |
| 2025 10 | 43 | 10 | 53 |
| 2025 9 | 41 | 6 | 47 |
| 2025 8 | 40 | 6 | 46 |
| 2025 7 | 45 | 12 | 57 |
| 2025 6 | 49 | 10 | 59 |
| 2025 5 | 22 | 2 | 24 |
| 2025 4 | 30 | 2 | 32 |
| 2025 3 | 46 | 5 | 51 |
| 2025 2 | 23 | 3 | 26 |
| 2025 1 | 40 | 0 | 40 |
| 2024 12 | 27 | 3 | 30 |
| 2024 11 | 37 | 3 | 40 |
| 2024 10 | 44 | 2 | 46 |
| 2024 9 | 61 | 5 | 66 |
| 2024 8 | 32 | 1 | 33 |
| 2024 7 | 48 | 2 | 50 |
| 2024 6 | 59 | 3 | 62 |
| 2024 5 | 49 | 3 | 52 |
| 2024 4 | 28 | 5 | 33 |
| 2024 3 | 40 | 5 | 45 |
| 2024 2 | 37 | 2 | 39 |
| 2024 1 | 51 | 0 | 51 |
| 2023 12 | 52 | 3 | 55 |
| 2023 11 | 69 | 3 | 72 |
| 2023 10 | 83 | 3 | 86 |
| 2023 9 | 29 | 3 | 32 |
| 2023 8 | 24 | 0 | 24 |
| 2023 7 | 54 | 5 | 59 |
| 2023 6 | 54 | 1 | 55 |
| 2023 5 | 51 | 1 | 52 |
| 2023 4 | 67 | 1 | 68 |
| 2023 3 | 55 | 1 | 56 |
| 2023 2 | 55 | 7 | 62 |
| 2022 1 | 47 | 14 | 61 |
| 2022 12 | 44 | 14 | 58 |
| 2022 11 | 45 | 24 | 69 |
| 2022 10 | 58 | 29 | 87 |
| 2022 9 | 45 | 11 | 56 |
| 2022 8 | 37 | 19 | 56 |
| 2022 7 | 25 | 13 | 38 |
| 2022 6 | 33 | 10 | 43 |
| 2022 5 | 42 | 9 | 51 |
| 2022 4 | 46 | 18 | 64 |
| 2022 3 | 46 | 14 | 60 |
| 2022 2 | 38 | 8 | 46 |
| 2021 1 | 66 | 9 | 75 |
| 2021 12 | 50 | 16 | 66 |
| 2021 11 | 51 | 8 | 59 |
| 2021 10 | 49 | 16 | 65 |
| 2021 9 | 28 | 11 | 39 |
| 2021 8 | 27 | 3 | 30 |
| 2021 7 | 30 | 12 | 42 |
| 2021 6 | 30 | 11 | 41 |
| 2021 5 | 42 | 7 | 49 |
| 2021 4 | 54 | 49 | 103 |
| 2021 3 | 64 | 11 | 75 |
| 2021 2 | 27 | 5 | 32 |
| 2020 1 | 45 | 14 | 59 |
| 2020 12 | 36 | 15 | 51 |
| 2020 11 | 40 | 13 | 53 |
| 2020 10 | 30 | 13 | 43 |
| 2020 9 | 30 | 12 | 42 |
| 2020 8 | 52 | 8 | 60 |
| 2020 7 | 39 | 8 | 47 |
| 2020 6 | 32 | 13 | 45 |
| 2020 5 | 84 | 11 | 95 |
| 2020 4 | 16 | 6 | 22 |
| 2020 3 | 22 | 8 | 30 |
| 2020 2 | 20 | 9 | 29 |
| 2020 1 | 15 | 6 | 21 |
| 2019 12 | 24 | 5 | 29 |
| 2019 11 | 16 | 12 | 28 |
| 2019 10 | 21 | 9 | 30 |
| 2019 9 | 34 | 8 | 42 |
| 2019 8 | 17 | 6 | 23 |
| 2019 7 | 30 | 7 | 37 |
| 2019 6 | 23 | 15 | 38 |
| 2019 5 | 45 | 52 | 97 |
| 2019 4 | 44 | 15 | 59 |
| 2019 3 | 16 | 8 | 24 |
| 2019 2 | 17 | 4 | 21 |
| 2019 1 | 7 | 7 | 14 |
| 2018 12 | 10 | 6 | 16 |
| 2018 11 | 31 | 8 | 39 |
| 2018 10 | 30 | 3 | 33 |
| 2018 9 | 26 | 7 | 33 |
| 2018 8 | 11 | 0 | 11 |
| 2018 7 | 12 | 1 | 13 |
| 2018 6 | 15 | 2 | 17 |
| 2018 5 | 15 | 0 | 15 |
| 2018 4 | 14 | 1 | 15 |
| 2018 3 | 6 | 1 | 7 |
| 2018 2 | 13 | 3 | 16 |
| 2018 1 | 8 | 5 | 13 |
| 2017 12 | 3 | 4 | 7 |
| 2017 10 | 1 | 0 | 1 |
| 2016 12 | 1 | 0 | 1 |
| 2016 11 | 0 | 1 | 1 |
| 2016 10 | 0 | 2 | 2 |
| 2016 9 | 0 | 2 | 2 |
| 2016 8 | 0 | 2 | 2 |
| 2016 7 | 0 | 1 | 1 |
| 2016 6 | 0 | 2 | 2 |
| 2016 5 | 0 | 1 | 1 |
| 2016 4 | 0 | 1 | 1 |
| 2016 3 | 1 | 1 | 2 |
| 2015 1 | 6 | 2 | 8 |
| 2015 12 | 4 | 4 | 8 |
| 2015 11 | 4 | 4 | 8 |
Mostrar todo
